Rapid UTI Diagnostics for Urinary Tract Infection
What You Need to Know Before You Apply
What is the purpose of this trial?
Patients who seek care through MedStar National Rehab Hospital's clinic believing they have a UTI will be enrolled in this trial. They will be pre-screened after consent according to a standard-of-care clinical symptom measure called the USQNB. If determined by this measure to be at high or moderate likelihood of having a UTI, they will be assigned to the presumed UTI arm and instructed to come to the clinic to provide a urine sample and undergo standard diagnostic testing to determine if a UTI is present. Those not assigned to the presumed UTI arm at this phase are assigned to the presumed no UTI arm and do not present to the clinic. These tests include a repeated questionnaire about the UTI symptoms they are experiencing and collection of a urine sample from a freshly changed indwelling catheter for standard clinical urinalysis testing and culture. Based upon the clinical guideline-informed results of these standard clinical tests, patients will be assigned into one of two potential arms (suspected UTI or suspected non-UTI) based on whether or not they are diagnosed with UTI at that visit.
Arm 1 (presumed UTI) participants will have a second urine sample collected at the time of the visit from the used indwelling catheter bag in addition to the freshly changed catheter sample, and both will be divided into three portions: one for repeat clinical tests and culture, one for assessment using the experimental Jiddu device, and one to be stored for potential future studies. The study doctor will then determine antibiotic choice according to standard clinical decision making and record, but not prescribe, that choice. Once results are obtained from the samples sent for experimental analysis, the study doctor will use those results in addition to their best clinical judgement and all standard available clinical evidence to choose the antibiotic treatment. Arm 1 participants will then complete urine symptom surveys at day 3 and 7 during antibiotic use to determine effectiveness of antibiotics prescribed. In the event of standard urine culture results differing from the Jiddu-produced pooled AST values rescue antibiotic consisting of the antibiotic choice based on best clinical judgement using this newly available evidence will be used to ensure safety and this survey clock will restart and include a USQNB on day 10.
Arm 2 participants will repeat the urinary symptoms questionnaire 3 and 7 days after their initial completion to see if their symptoms have changed and would allow them to qualify. If they remain unqualified at 7 days, they will be instructed to fill out another survey the next time they think they have a UTI. This process will repeat until they either qualify to become an Arm 1 participant or 6 months have passed since they first consented.
Who Is on the Research Team?
Ana Valeria Aguirre Guemez, MD
Principal Investigator
Medstar Health Research Institute
Are You a Good Fit for This Trial?
This trial is for adults (18+) who use a catheter to manage their bladder, have a neurogenic bladder diagnosis, and think they might have a UTI. People can't join if they've recently taken antibiotics for UTI or are in another conflicting study, or if they have conditions that make it hard to follow instructions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Initial Assessment and Sample Collection
Participants undergo initial assessment and urine sample collection for diagnostic testing
Treatment
Participants in the presumed UTI arm receive antibiotic treatment based on diagnostic results
Follow-up
Participants are monitored for symptom changes and effectiveness of treatment
Long-term Monitoring
Participants continue to complete symptom surveys over a 6-month period to monitor for new UTI symptoms
What Are the Treatments Tested in This Trial?
Trial Overview
The study compares standard urine tests with an experimental rapid test (using the Jiddu device) to diagnose UTIs in catheter users. Participants provide urine samples and answer symptom surveys; some may get additional testing based on results.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
When a participant develops symptoms suggestive of UTI, they will present to clinic and complete the USQNB. If they are still considered to have a moderate or high likelihood of UTI, they will provide urine from a fresh catheter to determine if they are a screen pass: 1. High or moderate profile per USQNB within the past 24 hours; and 2. Dipstick-determined Nitrite (N) \& Leukocyte Esterase (LE) are "strong positive" (both N positive and LE moderate or large), "inflammation positive" (N=negative and LE=moderate or large), or "indeterminate" (either LE=small with N positive or negative; or LE=negative or trace and N positive). Individuals who meet the definition of screen pass will provide a second urine sample from the bag and will be prescribed antibiotics to treat the UTI based on best clinical judgement using all available evidence, including the results provided by the experimental diagnostic device. After completion of the antibiotics, participants will have completed the study.
Participants will be classified as "screen fail" if they do not have at least one new-onset symptom on the USQNB of type A and at least one new on-set symptom of type B (B1 or B2) within the last 24 hours). These participants will then be consented and he or she will be considered a screen fail. Participants who screen fail will repeat the USQNB on days 3 and 7, or if new symptoms occur at any point during the 7 days following screening (using REDCap for follow-up). If their symptom profile does not change to meet screen pass criteria during this period, they will continue to be in the study and will only complete the USQNB thereafter if they have new concerns for a UTI. Individuals who screen fail for UTI can continue to participate in the full 6-month study. If during that 6 month period, an individual in the Presumed no UTI arm develops symptoms that would qualify them for the Presumed UTI arm, they will then "crossover" and begin that arm of the study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medstar Health Research Institute
Lead Sponsor
Loyola University Chicago
Collaborator
The Craig H. Neilsen Foundation
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.